Enhanced Immunogenicity of Cancer Vaccines using Saponins and Agonists of the Intracellular Stimulator of Interferon Genes Pathway

The inventive concept leverages the core technology of the original patent to enhance immunogenicity of cancer vaccines by combining them with agonists of the intracellular stimulator of interferon genes pathway, thereby improving treatment outcomes for cancer patients.

The original patent focused on improving influenza vaccine efficacy in elderly and immune-suppressed populations. However, cancer vaccines face similar challenges, with poor immunogenicity hindering treatment success. The inventive concept addresses this limitation by applying the original technology to cancer vaccines, offering a potential breakthrough in cancer treatment.

The inventive concept involves combining cancer vaccines with agonists of the intracellular stimulator of interferon genes pathway, such as Quillaja saponins QA-7, QA-17, QA-18, and QA-21. This synergy enhances the immunogenicity of cancer vaccines, leading to improved treatment outcomes. The agonists stimulate the immune system, increasing the recognition and attack of cancer cells. The inventive concept encompasses various administration routes, including intravenous and intratumoral, to optimize the immune response.

The inventive concept's novelty lies in its application of the original patent's technology to the field of cancer vaccines, providing a new and non-obvious solution to the problem of poor immunogenicity in cancer treatment. The combination of cancer vaccines with agonists of the intracellular stimulator of interferon genes pathway constitutes an inventive step, as it was not previously considered in the original patent.

Alternative embodiments of the inventive concept could include the use of different saponin mixtures, varying administration routes, or combining the agonists with other immunomodulators. Additionally, the inventive concept could be adapted for use in other diseases, such as autoimmune disorders or infectious diseases, where enhanced immunogenicity is desirable.

The inventive concept has significant commercial potential in the cancer vaccine market, which is expected to grow substantially in the coming years. The technology could be licensed to pharmaceutical companies or used to develop new cancer vaccines, offering a competitive advantage in the market. The target industries include oncology, immunotherapy, and vaccine development.